HRAS and urinary bladder cancer: The antiproliferative activity of the designed G4-decoys was tested in two types of cells: HeLa and T24 urinary bladder cancer cells that harbour a mutant HRAS [codon 12 GGC (Gly) is changed in GTC (Val)], expressing a hyperactivated HRAS protein [44].